论文部分内容阅读
目的：观察重组干扰素α－2a，α－2b抗病毒的近、远期疗效。方法：重组干扰素α－2a治疗组64例，重组干扰素α－2b组％例及对照组20例，治疗后随访5年。结果：治疗结束时，HCVRNA阴转率和血清ALT复常率α－2a组分别为67．18％和70．13％，α－2b组分别为69．14％和72．22％；随访5年后，HCVRNA阴转率和血清ALT复常率α-2a组分别为35．93%和46．87%，α－2b组分别为38.88%和50.00%，均显著高于对照组（P＜0．01和P＜0．05）。治疗组病情稳定率49．0％高于对照组（P＜0．01），病情稳定的比率又以血清HCVRNA和肝组织内HCVRNA检测明性者为高（P＜0．05）。结论：重组干扰素α－2a与α－2b均为有效的抗丙型肝炎病毒药物，慢性丙型肝炎患者干扰素治疗的早期疗效较好，但完全应答者的复发率较高。
Objective: To observe the short-term and long-term effects of recombinant interferon alpha-2a and alpha-2b antiviral drugs. Methods: Sixty-four patients were treated with recombinant interferon α-2a, 20% were treated with recombinant interferon α-2b, and 20 were treated by control. The patients were followed up for 5 years. Results: At the end of treatment, 67.18% and 70.13% in the α-2a group and 69.14% in the α-2b group and 72.22% in the α-2b group were significantly higher than those in the control group After year, the negative rates of HCV RNA and ALT in α-2a group were 35.93% and 46.87% respectively, and those in α-2b group were 38.88% and 50.00%, respectively, which were significantly higher than those in control group (P < 0.01 and P <0.05). The stable rate of disease in the treatment group was higher than that in the control group (49.0%, P <0.01). The stable disease rate was higher in the serum HCVRNA and HCVRNA in the liver tissue (P <0.05). Conclusion: Recombinant interferon α-2a and α-2b are effective anti-hepatitis C virus drugs. Interferon treatment in patients with chronic hepatitis C has better early response, but patients with complete response have a higher relapse rate.